Orsetta Quaini

Orsetta Quaini

Auto-generated profile, based on publicly available information

Orsetta Quaini

Department of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
GFGian Marco Franceschini
Gian Marco Franceschini
OQOrsetta Quaini
Orsetta Quaini
KMKei Mizuno
Kei Mizuno
FOFrancesco Orlando
Francesco Orlando
YCYari Ciani
Yari Ciani
HBHimisha Beltran
Himisha Beltran
Castration-resistant prostate cancer (CRPC) is a heterogeneous disease associated with phenotypic subtypes that drive therapy response and outcome differences. Histologic transformation to castration-resistant neuroendocrine prostate cancer (CRPC-NE) is associated with distinct epigenetic alterations, including changes in DNA methylation. The current diagnosis of CRPC-NE is challenging and relies on metastatic biopsy. We developed a targeted DNA methylation assay to detect CRPC-NE using plasma cell-free DNA (cfDNA). The assay quantifies tumor content and provides a phenotype evidence score that captures diverse CRPC phenotypes, leveraging regions to inform transcriptional state. We tested the design in independent clinical cohorts (n = 222 plasma samples) and qualified it achieving an AUC > 0.93 for detecting pathology-confirmed CRPC-NE (n = 136). Methylation-defined cfDNA tumor content was associated with clinical outcomes in two prospective phase II clinical trials geared towards aggressive variant CRPC and CRPC-NE. These data support the application of targeted DNA methylation for CRPC-NE detection and patient stratification. Significance: Neuroendocrine prostate cancer is an aggressive subtype of treatment-resistant prostate cancer. Early detection is important, but the diagnosis currently relies on metastatic biopsy. We describe the development and validation of a plasma cell–free DNA targeted methylation panel that can quantify tumor fraction and identify patients with neuroendocrine prostate cancer noninvasively. This article is featured in Selected Articles from This Issue, p. 384

13 June 2025 in Cancer Discovery
Verified
Journal Article
Open access
PGPaola Gasperini
Paola Gasperini
Alessandro AlaimoAlessandro Alaimo
Alessandro Alaimo
BSBlerta Stringa
Blerta Stringa
YCYoon-Mi Chung
Yoon-Mi Chung
YCYari Ciani
Yari Ciani
FDFrancesca Demichelis
Francesca Demichelis
The biological mechanisms underlying the cooperation between germline genetic variants and somatic mutations during carcinogenesis are rarely elucidated. In this study, characterizing isogenic prostate cancer cell lines, we dissected the interplay between a germline variant at the 7p14.3 locus (rs1376350, G>A) and early recurrent prostate cancer–specific mutation in the speckle-type POZ protein (SPOP) gene across human prostate adenocarcinomas. The transcriptomes of multiple edited models pointed to GLI3 and the Hedgehog signaling pathway in a genotype-specific manner, whereas SPOP mutation and androgen receptor stimulation promote GLI3 accumulation in the full-length, transcriptionally active form. This, in turn, triggers the cell-autonomous production of steroids that prostate cancer relies on, in line with the enhanced responsiveness of SPOP-mutated prostate cancer to androgen deprivation therapy. These data demonstrate that germline variants dictate prostate cancer somatic evolution and suggest opportunities to jointly model germline–somatic relationship to help untangle the complexity of human cancer. Significance: Significant heritability is observed for common cancer types worldwide. The molecular mechanisms by which inherited genetics facilitate cancer initiation might transit through its cooperation with specific somatic events that then dictate the tumor features. Through a germline–somatic tandem leading to steroid biosynthesis, we suggest a paradigm to study cancer initiation.

16 September 2026 in iScience
Verified
Journal Article
Open access
ICIlaria Cherchi
Ilaria Cherchi
FOFrancesco Orlando
Francesco Orlando
OQOrsetta Quaini
Orsetta Quaini
MPMarta Paoli
Marta Paoli
YCYari Ciani
Yari Ciani
FDFrancesca Demichelis
Francesca Demichelis

1 March 2024
Verified
Other
Open access
GFGian Marco Franceschini
Gian Marco Franceschini
OQOrsetta Quaini
Orsetta Quaini
KMKei Mizuno
Kei Mizuno
FOFrancesco Orlando
Francesco Orlando
YCYari Ciani
Yari Ciani
HBHimisha Beltran
Himisha Beltran
Supp. Fig. 1 Differential methylation across prostate cancer disease states Supp. Fig. 2 NEMO panel design Supp. Fig. 3 Tumor content estimation with a minimal set of informative regions Supp. Fig. 4 Scoring CRPC-NE in circulation with the phenotype evidence (PE) score Supp. Fig. 5 Probing the CRPC spectrum with NEMO Supp. Fig. 6 Clinical utility of the NEMO assay Supp. Fig. 7 Copy number estimation using the NEMO assay

1 March 2024
Verified
Other
Open access
GFGian Marco Franceschini
Gian Marco Franceschini
OQOrsetta Quaini
Orsetta Quaini
KMKei Mizuno
Kei Mizuno
FOFrancesco Orlando
Francesco Orlando
YCYari Ciani
Yari Ciani
HBHimisha Beltran
Himisha Beltran
S1: Motif enrichment results around differentially methylated sites in CRPC-NE vs CRPC-Adeno solid tissue biopsy eRRBS data (Beltran2016) S2A: PSA and treatment timepoints for the PRIME cohort S2BPSA and treatment timepoints for the Wu2020 cohort S3Sequencings statistics for samples profiled with the NEMO panel (Notice that sequencing run and Dataset might differ) S4: NEMO tumor content (TC) and PE score estimation of all study samples (NEMO generated and reprocessed data) S5: Association between gene expression and proximal DNA methylation for the PDX EPIC cohort (pdx) and WCDT cohort (biopsies) S6A: Alisertib cohort survival data S6B: Chemo trial cohort survival data S7: Inclusion criteria for the two phase 2 trial cohorts S8:References of masked samples and samples sequenced in this work S9: Description of informative regions included in the NEMO panel S10: Mean CpG coverage in NEMO regions for reprocessed data (only CpG sites with at least 10x coverage are retained)

7 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
FVFederico Vannuccini
Federico Vannuccini
YCYari Ciani
Yari Ciani
VMVera Mugoni
Vera Mugoni
OQOrsetta Quaini
Orsetta Quaini
FOFrancesco Orlando
Francesco Orlando
FDFrancesca Demichelis
Francesca Demichelis
Circulating analytes in cancer patients capture tumor-related signals. We profiled matched extracellular vesicle (EV) total RNA and cell-free DNA (cfDNA) from the same plasma aliquots of chemo-naive metastatic castration-resistant prostate cancer (mCRPC) patients treated with Enzalutamide (n=54 patients, n=119 longitudinal samples; NCT06981377 ) at four Italian clinical centers and interrogated data from >10,000 cancer patients’ and healthy individuals’ samples. Transcript integrity analysis identified coding and non-coding species with fragmentation patterns varying across RNA biotypes. EV-RNA data deconvolution revealed signal from immune populations, including fractions classified as CD4+ T cells, whose abundance increased with disease progression in plasma EVs and mCRPC tissues. By leveraging tissue data-informed mining, we established a novel prostate cancer-related EV-RNA signature that resulted in an independent predictor of poor prognosis and captured tumor microenvironment-derived signals. Integrating EV-RNA and ctDNA information improved patient stratification for progression-free survival. These findings suggest a multifaceted role for plasma EVs as a source of cancer biomarkers. Statement of significance: EV-RNA provides biologically relevant tumor and immune-derived signals in mCRPC. Integration with cfDNA improves patient stratification, highlighting EVs as a complementary source of translational information for monitoring disease progression and therapeutic response in prostate cancer.